Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact

Rhea-AI Summary

Illumina (NASDAQ: ILMN) released its 2025 Corporate Responsibility Report, emphasizing expanded access to genomics and global impact. Highlights include sequencing over 10 human genomes per minute in 2025, major sustainability gains, workforce equity, large-scale community engagement, and new product launches that broaden research, clinical, and population health applications.

Positive

• Sequencing throughput exceeded 10 human genomes per minute in 2025
• Product packaging reduced 87% since 2019, surpassing 2030 target
• Scope 1 and 2 greenhouse gas emissions reduced 74% since 2019
• 100% renewable electricity achieved for four consecutive years
• Zero net pay gap maintained for seven consecutive years
• More than 116,000 employee volunteer hours contributed since 2019
• 2.6 million STEM learners reached globally since 2019
• Launch of Illumina 5-base solution and Illumina Protein Prep in 2025
• Updated DRAGEN pipeline and expanded oncology portfolio in 2025
• Recognition twice in TIME's World's Most Sustainable Companies list

Negative

• None.

News Market Reaction – ILMN

+0.17%

+0.17% Session close to close

In the May 20 session, ILMN gained 0.17%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement emphasizes Illumina’s sustainability and social-impact trajectory, including an 87...

Analysis

This announcement emphasizes Illumina’s sustainability and social-impact trajectory, including an 87% reduction in packaging, 74% lower Scope 1 and 2 emissions, and 100% renewable electricity for four consecutive years. It also highlights community outreach, with 116,000 volunteer hours and 2.6 million STEM learners reached since 2019. In context of recent revenue growth to $1.09B and raised 2026 guidance, investors may monitor how these ESG efforts support long-term brand strength and stakeholder relationships.

Key Figures

Annual cancer diagnoses: more than 20 million people Sequencing throughput: over 10 human genomes per minute Packaging reduction: 87% reduction +5 more

8 metrics

Annual cancer diagnoses more than 20 million people Global cancer diagnoses per year mentioned in CR report

Sequencing throughput over 10 human genomes per minute Sequencing pace on Illumina platforms in 2025

Packaging reduction 87% reduction Product packaging reduction since 2019 vs 2030 target

GHG emissions reduction 74% reduction Scope 1 and 2 greenhouse gas emissions since 2019

Renewable electricity 100% for four years Use of renewable electricity for fourth consecutive year

Volunteer hours more than 116,000 hours Cumulative employee volunteer hours since 2019

STEM learners reached 2.6 million learners Total STEM learners reached since 2019

STEM learners in 2025 500,000 learners STEM learners reached in 2025 alone

Historical Context

5 past events · Latest: Apr 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	Q1 2026 earnings	Positive	+7.1%	Revenue growth, margin expansion, and raised 2026 guidance with new buyback.
Apr 16	Product update	Positive	+0.3%	Launch of DRAGEN v4.5 expanding germline, oncology, and multiomic analysis.
Apr 14	Data partnership	Positive	+2.6%	Partnership to analyze 100,000 pediatric whole genomes on cloud platform.
Apr 09	Earnings date set	Neutral	-2.2%	Announcement of timing for Q1 2026 financial results and conference call.
Apr 02	Board changes	Positive	+0.6%	Retirement of directors and nomination of David P. King to the Board.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has generally seen positive price alignment, especially around earnings, product launches, and strategic partnerships.

Recent Company History

Over the last few months, Illumina reported solid Q1 FY2026 results with $1.09B revenue, expanding margins, higher EPS, and raised full‑year guidance, which drew a 7.13% positive reaction on Apr 30. Product and software updates, including DRAGEN v4.5 and a large-scale pediatric genomics data partnership, also saw modest gains. Board refresh news in early April was received positively. Against this backdrop, the 2025 Corporate Responsibility report extends an existing narrative of operational strength, innovation, and long-term ESG positioning rather than introducing a new financial catalyst.

Key Terms

next-generation sequencing, scope 1 and 2 greenhouse gas emissions, renewable energy credits, oncology, +2 more

6 terms

next-generation sequencing medical

"bring next-generation sequencing to patients without access"

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

scope 1 and 2 greenhouse gas emissions technical

"reduced Scope 1 and 2 greenhouse gas emissions by 74%"

Scope 1 and 2 greenhouse gas emissions are the carbon and other greenhouse gases a company produces directly and indirectly from its energy use: Scope 1 covers emissions from sources the company owns or controls (like fuel burned in company vehicles or boilers), while Scope 2 covers emissions tied to purchased electricity, heat or steam. Investors care because these emissions affect regulatory costs, operating expenses, reputation and long-term risk exposure — like a company’s “tailpipe” and its “electric bill” for climate impact.

renewable energy credits technical

"renewable electricity ... through ... renewable energy credits (RECs)"

Renewable energy credits (RECs) are tradable certificates that prove one megawatt-hour of electricity was generated from a renewable source, separate from the physical electricity itself. Think of a REC as a receipt for supporting green power: companies buy or sell them to meet regulatory targets or sustainability goals. Investors pay attention because RECs create additional revenue or cost obligations, influence corporate environmental claims, and can affect the economics and valuation of clean‑energy projects.

oncology medical

"expanded our oncology portfolio"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

population-scale genomics medical

"population-scale genomics, sovereign data stewardship"

Population-scale genomics is the large-scale reading and analysis of DNA from tens of thousands to millions of people to map how genetic differences relate to health, traits and disease risk. Think of it as a genetic census that reveals patterns and rare signals you can't see in small studies; for investors it creates valuable data assets and potential markets for new drugs, diagnostics and personalized treatments while also raising regulatory, privacy and commercialization considerations.

sovereign data stewardship technical

"population-scale genomics, sovereign data stewardship"

Sovereign data stewardship is a government’s practice of controlling, protecting and setting rules for data about its citizens, businesses and territory—like a homeowner deciding who may enter and what they may take. For investors it matters because these rules shape where companies can store and move data, the cost of compliance, access to markets, and legal risk; stronger controls can raise costs but also create predictable frameworks for doing business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 19, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today published its annual Corporate Responsibility (CR) Report. The report highlights the company's continued progress in expanding equitable access to genomics while delivering measurable impact for patients, communities, and health systems worldwide. It reinforces Illumina's mission-driven culture, sustainability goals, and commitment to genomics for good.

"More than 20 million people are diagnosed with cancer each year. Rare disease patients face years-long diagnostic odysseys to find answers. Health systems are under growing pressure to deliver better outcomes with fewer resources. Genomics can help meet these challenges, but only if it is integrated into real-world settings at scale," said Jacob Thaysen, CEO of Illumina. "The exceptional pace of sequencing on Illumina platforms—over 10 human genomes per minute in 2025—is a strong signal that we are meeting the moment, bringing us closer to a future where personalized medicine improves outcomes for all."

Expanding access to genomics at scale across the globe

Illumina is enabling cost-effective, scalable technologies while championing global policies and initiatives to improve access to genomic medicine. In 2025, Illumina partnered with governments, health systems, and research institutions for population-scale genomics, sovereign data stewardship, and national precision health initiatives that reflect local needs and priorities. The Illumina Corporate Foundation supported efforts around the world to bring next-generation sequencing to patients without access. Illumina contributed to international policy efforts to prioritize rare disease in public health and participated in rare disease hackathons where our new technologies and employee expertise interrogated genomic challenges.

Continuing leadership in sustainability, community engagement

Illumina recognizes that human health and environmental health are fundamentally linked, driving the company to reduce its environmental footprint across business practices while supporting customers' ability to sequence more sustainably. Since 2019, Illumina has reduced product packaging by 87%, surpassing its 2030 target. Over the same period, the company has reduced Scope 1 and 2 greenhouse gas emissions by 74% and achieved 100% renewable electricity for the fourth consecutive year through renewable energy procurement, onsite solar generation, and renewable energy credits (RECs). These efforts earned Illumina recognition as one of TIME's World's Most Sustainable Companies for the second year in a row.

Reflecting the company's commitment to nurturing our people and community, Illumina maintained a zero net pay gap for the seventh consecutive year and surpassed its goal of 100,000 volunteer hours by 2030. Employees have contributed more than 116,000 volunteer hours since 2019, with 50% of employees participating in giving and volunteering opportunities in 2025. Employees routinely bring their passion for education to the classroom, investing in the next generation of scientists. Illumina has reached 2.6 million STEM learners since 2019, including 500,000 in 2025 alone.

As part of the company's dedication to innovation, Illumina continues to expand access to genomic technologies across research, clinical, and population health settings. In 2025, the company launched the Illumina 5-base solution and Illumina Protein Prep, updated the DRAGEN software pipeline, and expanded our oncology portfolio. Illumina also debuted new capabilities such as PromoterAI and strengthened global collaborations with the Alliance for Genomic Discovery, Broad Clinical Labs, and more.

Illumina is pleased to share all of this information and more in its 2025 Corporate Responsibility report, available here.

Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements regarding Illumina's expectations, plans, and the potential impact of its technologies and initiatives, and are based on Illumina's current expectations, assumptions, and beliefs. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  Forward-looking statements may be identified by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "project," "seek," "will," and similar expressions. Factors that could cause actual results to differ materially include, among others: challenges inherent in developing and commercializing new technologies; the rate of adoption of genomic solutions by customers and health systems; regulatory developments and reimbursement considerations; and other factors described in Illumina's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Illumina undertakes no obligation to update any forward-looking statements except as required by law.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. 

Illumina Contacts:  

Investors:
Illumina Investor Relations  
858-291-6421  
IR@illumina.com 

Media: 
Christine Douglass  
PR@illumina.com 

View original content:https://www.prnewswire.com/news-releases/illumina-releases-2025-corporate-responsibility-report-expanding-access-to-genomics-and-accelerating-global-impact-302775660.html

SOURCE Illumina, Inc.

FAQ

What does Illumina's 2025 Corporate Responsibility Report reveal about ILMN's genomics impact?

Illumina reports expanding access to genomics and measurable benefits for patients, communities, and health systems. According to Illumina, sequencing on its platforms reached over 10 human genomes per minute in 2025, supporting broader adoption of precision medicine worldwide.

How is Illumina (ILMN) improving global access to genomic medicine in 2025?

Illumina is partnering with governments, health systems, and research institutions on population-scale genomics and precision health initiatives. According to Illumina, it also supports sovereign data stewardship and funds next-generation sequencing access for underserved patients through the Illumina Corporate Foundation.

What sustainability milestones did Illumina (ILMN) report in its 2025 Corporate Responsibility update?

Illumina reported sharp reductions in packaging and emissions alongside full renewable electricity use. According to Illumina, product packaging is down 87% since 2019, Scope 1 and 2 emissions fell 74%, and 100% renewable electricity was achieved for the fourth straight year.

How does Illumina's 2025 Corporate Responsibility Report address workforce equity and community impact?

Illumina highlights pay equity, volunteering, and STEM outreach achievements. According to Illumina, it maintained a zero net pay gap for the seventh year, logged over 116,000 volunteer hours since 2019, and reached 2.6 million STEM learners, including 500,000 in 2025.

What new genomics products and technologies did Illumina (ILMN) feature in its 2025 CR Report?

Illumina detailed multiple product launches that expand genomic applications. According to Illumina, 2025 introductions included the Illumina 5-base solution, Illumina Protein Prep, DRAGEN pipeline updates, new oncology portfolio offerings, and PromoterAI, alongside expanded collaborations with global genomics partners.

Why was Illumina (ILMN) named to TIME's World's Most Sustainable Companies list again?

Illumina attributes this recognition to its environmental and social performance. According to Illumina, packaging and emissions reductions, continuous 100% renewable electricity, and integrated sustainability practices contributed to being named one of TIME's World's Most Sustainable Companies for the second consecutive year.